YaoGeJu

Company directoryChina company filings

Hangzhou He Kang Pharma Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 2ab5bd5648

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

29 acceptance records as first applicant, grouped into 15 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Dotinurad Tablets 2 records · Latest accepted 2026/05/08

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601051Generic2026/05/08Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2601050Generic2026/05/08Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
西诺氨酯片 · No verified English name 3 records · Latest accepted 2026/01/20

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600225Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2600224Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2600223Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Rasagiline Mesylate Tablets 2 records · Latest accepted 2026/01/15

Supplement · 1Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2600084Supplement2026/01/15Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2300725Generic2023/03/07Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Mirogabalin Besilate Tablets 2 records · Latest accepted 2025/08/20

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503060Generic2025/08/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2503059Generic2025/08/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Brexpiprazole Tablets 3 records · Latest accepted 2025/05/29

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501924Generic2025/05/29Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501923Generic2025/05/29Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501922Generic2025/05/29Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Brexpiprazole Orally Disintegrating Tablets 3 records · Latest accepted 2025/05/23

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501864Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501863Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501862Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Riociguat Tablets 3 records · Latest accepted 2025/04/17

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501470Generic2025/04/17Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501469Generic2025/04/17Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501468Generic2025/04/17Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Minocycline Hydrochloride Capsules 2 records · Latest accepted 2025/04/09

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501367Generic2025/04/09Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2501366Generic2025/04/09Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Oxcarbazepine Tablets 2 records · Latest accepted 2025/01/04

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500064Generic2025/01/04Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2500063Generic2025/01/04Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
托吡酯口服溶液 · No verified English name 1 records · Latest accepted 2024/12/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404585Generic2024/12/27Hangzhou He Kang Pharma Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
Safinamide Methansulfonate Tablets 2 records · Latest accepted 2024/12/27

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404580Generic2024/12/27Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
CYHS2404579Generic2024/12/27Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
盐酸雷莫司琼缓释贴片 · No verified English name 1 records · Latest accepted 2024/11/21

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHB2400253Supplement2024/11/21Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Vortioxetine Hydrobromide Tablets 1 records · Latest accepted 2023/07/13

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2301881Generic2023/07/13Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Aripiprazole Orally Disintegrating tablets 1 records · Latest accepted 2023/02/23

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300617Generic2023/02/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Memantine Hydrochloride Oral Solution 1 records · Latest accepted 2022/02/08

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200221Generic2022/02/08Hangzhou He Kang Pharma Co., Ltd. romanized; Zhejiang Kang En Bei Pharmaceutical Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

12 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Dotinurad Tablets CYHS2601051Generic2026/05/08Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Dotinurad Tablets CYHS2601050Generic2026/05/08Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
西诺氨酯片 · No verified English name CYHS2600225Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
西诺氨酯片 · No verified English name CYHS2600224Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
西诺氨酯片 · No verified English name CYHS2600223Generic2026/01/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Mirogabalin Besilate Tablets CYHS2503060Generic2025/08/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Mirogabalin Besilate Tablets CYHS2503059Generic2025/08/20Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Brexpiprazole Orally Disintegrating Tablets CYHS2501864Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Brexpiprazole Orally Disintegrating Tablets CYHS2501863Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Brexpiprazole Orally Disintegrating Tablets CYHS2501862Generic2025/05/23Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Minocycline Hydrochloride Capsules CYHS2501367Generic2025/04/09Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗
Minocycline Hydrochloride Capsules CYHS2501366Generic2025/04/09Hangzhou He Kang Pharma Co., Ltd. romanizedCDE ↗

Catalogue holder records

10 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Safinamide Methansulfonate TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202657842026/09/02Generic approved under the new chemical-drug registration classificationCDE ↗
Safinamide Methansulfonate TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202657832026/09/02Generic approved under the new chemical-drug registration classificationCDE ↗
Riociguat TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202654342026/07/28Generic approved under the new chemical-drug registration classificationCDE ↗
Riociguat TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202654332026/07/28Generic approved under the new chemical-drug registration classificationCDE ↗
Oxcarbazepine TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202652472026/07/21Generic approved under the new chemical-drug registration classificationCDE ↗
Oxcarbazepine TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202652482026/07/21Generic approved under the new chemical-drug registration classificationCDE ↗
Vortioxetine Hydrobromide TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202495942024/12/01Generic approved under the new chemical-drug registration classificationCDE ↗
Rasagiline Mesylate TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202447022024/08/20Generic approved under the new chemical-drug registration classificationCDE ↗
Aripiprazole Orally Disintegrating tabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202443172024/06/28Generic approved under the new chemical-drug registration classificationCDE ↗
Riociguat TabletsHangzhou He Kang Pharma Co., Ltd. romanizedHangzhou He Kang Pharma Co., Ltd. romanized国药准字H202654322026/07/28Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.